Kidney Transplant Clinical Trials

Clinical trials related to Kidney Transplant Procedure

A Seamless Phase 2/3 Randomized, Open-label Study to Investigate Efficacy and Safety of Frexalimab Versus Tacrolimus in Adult Kidney Transplant Recipients

Status: Recruiting
Location: See all (71) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

The purpose of this open-label, randomized, active-comparator-controlled study is to determine the efficacy and safety of frexalimab subcutaneous administrations up to 5 years compared to tacrolimus capsules in adults undergoing kidney transplantation. Participants aged 18 to 70 years who have low-to-moderate immunologic risk of graft rejection and receive their first kidney transplant are eligible if they meet all inclusion and no exclusion criteria. Study details include: * The study and treatment duration will be up to approximately 5 years. * The number of visits will be approximately 38.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: f
View:

• Participants who are scheduled to receive their first kidney transplant from a living or deceased donor.

• Participants with low to moderate immunological risk.

Locations
United States
California
University of California San Francisco - Parnassus Heights- Site Number : 8400001
RECRUITING
San Francisco
Georgia
Emory University Hospital- Site Number : 8400002
RECRUITING
Atlanta
Illinois
Edward Hines, Jr. Veterans Affairs Hospital- Site Number : 8400010
RECRUITING
Hines
Kansas
University of Kansas Medical Center- Site Number : 8400044
RECRUITING
Kansas City
Massachusetts
Brigham & Women's Hospital- Site Number : 8400049
RECRUITING
Boston
Maryland
University of Maryland School of Medicine - Baltimore- Site Number : 8400045
RECRUITING
Baltimore
Michigan
University of Michigan Health System - Ann Arbor- Site Number : 8400022
RECRUITING
Ann Arbor
New York
Columbia University Irving Medical Center- Site Number : 8400007
RECRUITING
New York
The Mount Sinai Hospital- Site Number : 8400027
RECRUITING
New York
Weill Cornell Medical College- Site Number : 8400005
RECRUITING
New York
Montefiore Medical Center - Moses Campus- Site Number : 8400006
RECRUITING
The Bronx
Ohio
The Ohio State University- Site Number : 8400025
RECRUITING
Columbus
Virginia
VCU Massey Cancer Center: Dalton Oncology Clinic- Site Number : 8400004
RECRUITING
Richmond
Washington
University of Washington Medical Center- Site Number : 8400035
RECRUITING
Seattle
Other Locations
Argentina
Investigational Site Number : 0320002
RECRUITING
Buenos Aires
Investigational Site Number : 0320001
RECRUITING
Corrientes
Australia
Investigational Site Number : 0360002
RECRUITING
Adelaide
Investigational Site Number : 0360004
RECRUITING
Clayton
Investigational Site Number : 0360001
RECRUITING
Parkville
Investigational Site Number : 0360003
RECRUITING
Sydney
Belgium
Investigational Site Number : 0560002
RECRUITING
Brussels
Investigational Site Number : 0560001
RECRUITING
Leuven
Brazil
Hospital Geral de Fortaleza - HGF- Site Number : 0760007
RECRUITING
Fortaleza
Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760004
RECRUITING
Porto Alegre
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760006
RECRUITING
São Paulo
Hospital do Rim e Hipertensão- Site Number : 0760001
RECRUITING
São Paulo
Chile
Investigational Site Number : 1520004
RECRUITING
Santiago
Investigational Site Number : 1520005
RECRUITING
Santiago
China
Investigational Site Number : 1560018
RECRUITING
Beijing
Investigational Site Number : 1560003
RECRUITING
Chengdu
Investigational Site Number : 1560007
RECRUITING
Guangzhou
Investigational Site Number : 1560020
RECRUITING
Guangzhou
Investigational Site Number : 1560002
RECRUITING
Hangzhou
Investigational Site Number : 1560012
RECRUITING
Jinan
Investigational Site Number : 1560017
RECRUITING
Nanchang
Investigational Site Number : 1560008
RECRUITING
Nanning
Investigational Site Number : 1560001
RECRUITING
Shanghai
Investigational Site Number : 1560016
RECRUITING
Shanghai
Investigational Site Number : 1560011
RECRUITING
Tianjin
Investigational Site Number : 1560006
RECRUITING
Wuhan
Investigational Site Number : 1560004
RECRUITING
Xi'an
Investigational Site Number : 1560005
RECRUITING
Zhengzhou
Investigational Site Number : 1560009
RECRUITING
Zhengzhou
Denmark
Investigational Site Number : 2080001
RECRUITING
Aarhus
Finland
Investigational Site Number : 2460001
RECRUITING
Helsinki
France
Investigational Site Number : 2500002
RECRUITING
Bordeaux
Investigational Site Number : 2500009
RECRUITING
Nantes
Investigational Site Number : 2500008
RECRUITING
Paris
Investigational Site Number : 2500001
RECRUITING
Toulouse
Investigational Site Number : 2500003
RECRUITING
Tours
Hungary
Investigational Site Number : 3480001
RECRUITING
Pécs
Israel
Investigational Site Number : 3760002
RECRUITING
Ramat Gan
Italy
Investigational Site Number : 3800003
RECRUITING
Bologna
Investigational Site Number : 3800009
RECRUITING
Brescia
Investigational Site Number : 3800005
RECRUITING
Milan
Investigational Site Number : 3800010
RECRUITING
Milan
Investigational Site Number : 3800011
RECRUITING
Novara
Investigational Site Number : 3800012
RECRUITING
Palermo
Investigational Site Number : 3800006
RECRUITING
Rome
Investigational Site Number : 3800008
RECRUITING
Torette
Netherlands
Investigational Site Number : 5280001
RECRUITING
Groningen
Investigational Site Number : 5280002
RECRUITING
Leiden
Spain
Investigational Site Number : 7240001
RECRUITING
Barcelona
Investigational Site Number : 7240007
RECRUITING
Barcelona
Investigational Site Number : 7240008
RECRUITING
Barcelona
Investigational Site Number : 7240003
RECRUITING
L'hospitalet De Llobregat
Investigational Site Number : 7240005
RECRUITING
Málaga
Sweden
Investigational Site Number : 7520001
RECRUITING
Gothenburg
Investigational Site Number : 7520003
RECRUITING
Huddinge
Investigational Site Number : 7520002
RECRUITING
Uppsala
United Kingdom
Investigational Site Number : 8260001
RECRUITING
Birmingham
Contact Information
Primary
Trial Transparency email recommended (Toll free for US & Canada)
Contact-US@sanofi.com
800-633-1610
Time Frame
Start Date: 2026-03-13
Estimated Completion Date: 2033-08-15
Participants
Target number of participants: 526
Treatments
Experimental: Frexalimab
The first dose of frexalimab will be given intravenously and subsequent doses of frexalimab will be administered subcutaneously via on-body delivery system(OBDS)
Active_comparator: Tacrolimus
Tacrolimus
Related Therapeutic Areas
Sponsors
Leads: Sanofi

This content was sourced from clinicaltrials.gov